The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
As of close of business last night, Twist Bioscience Corp’s stock clocked out at $28.16, down -8.42% from its previous closing price of $30.75. In other words, the price has decreased by -$8.42 from its previous closing price. On the day, 2.17 million shares were traded. TWST stock price reached its highest trading level at $31.02 during the session, while it also had its lowest trading level at $28.12.
Ratios:
To gain a deeper understanding of TWST’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.60 and its Current Ratio is at 3.90. In the meantime, Its Debt-to-Equity ratio is 0.16 whereas as Long-Term Debt/Eq ratio is at 0.13.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Wolfe Research on December 13, 2024, initiated with a Outperform rating and assigned the stock a target price of $60.
On June 04, 2024, Guggenheim started tracking the stock assigning a Buy rating and target price of $53.
Goldman Upgraded its Neutral to Buy on January 17, 2024, whereas the target price for the stock was revised from $25 to $45.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Oct 08 ’25 when Laponis Adam sold 3,000 shares for $31.15 per share. The transaction valued at 93,450 led to the insider holds 94,042 shares of the business.
Laponis Adam sold 2,517 shares of TWST for $82,865 on Oct 09 ’25. The Chief Financial Officer now owns 91,525 shares after completing the transaction at $32.92 per share. On Oct 09 ’25, another insider, Laponis Adam, who serves as the Officer of the company, bought 2,517 shares for $32.92 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TWST now has a Market Capitalization of 1699763584 and an Enterprise Value of 1542115584. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.69 while its Price-to-Book (P/B) ratio in mrq is 3.54. Its current Enterprise Value per Revenue stands at 4.257 whereas that against EBITDA is -12.909.
Stock Price History:
The Beta on a monthly basis for TWST is 2.40, which has changed by -0.3790518 over the last 52 weeks, in comparison to a change of 0.13837254 over the same period for the S&P500. Over the past 52 weeks, TWST has reached a high of $55.33, while it has fallen to a 52-week low of $24.07. The 50-Day Moving Average of the stock is 0.74%, while the 200-Day Moving Average is calculated to be -22.11%.
Shares Statistics:
It appears that TWST traded 1.69M shares on average per day over the past three months and 2059270 shares per day over the past ten days. A total of 60.17M shares are outstanding, with a floating share count of 57.71M. Insiders hold about 4.39% of the company’s shares, while institutions hold 115.82% stake in the company. Shares short for TWST as of 1759190400 were 12982960 with a Short Ratio of 7.70, compared to 1756425600 on 10234719. Therefore, it implies a Short% of Shares Outstanding of 12982960 and a Short% of Float of 24.270001.
Earnings Estimates
The stock of Twist Bioscience Corp (TWST) is currently in the spotlight, with 1.0 analysts actively rating and assessing its market standing.The consensus estimate for the next quarter is -$0.52, with high estimates of -$0.52 and low estimates of -$0.52.
Analysts are recommending an EPS of between -$1.34 and -$1.34 for the fiscal current year, implying an average EPS of -$1.34. EPS for the following year is -$1.76, with 1.0 analysts recommending between -$1.76 and -$1.76.
Revenue Estimates
In. The current quarter, 6 analysts expect revenue to total $97.4M. It ranges from a high estimate of $98M to a low estimate of $97M. As of. The current estimate, Twist Bioscience Corp’s year-ago sales were $84.71MFor the next quarter, 6 analysts are estimating revenue of $101.17M. There is a high estimate of $101.6M for the next quarter, whereas the lowest estimate is $100.8M.
A total of 6 analysts have provided revenue estimates for TWST’s current fiscal year. The highest revenue estimate was $375.5M, while the lowest revenue estimate was $374M, resulting in an average revenue estimate of $374.9M. In the same quarter a year ago, actual revenue was $312.97MBased on 6 analysts’ estimates, the company’s revenue will be $435.65M in the next fiscal year. The high estimate is $446M and the low estimate is $428.9M.
